Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L. +9 more·2005·Journal of Clinical Oncology
DOI 10.1200/jco.2005.06.205

Cited by (1,000)

Items 101–200 of 1,000

  1. Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
    Christy Ralph, Eyad Elkord, Deborah J. Burt, Jackie F. O'Dwyer, Eric B. Austin, Peter L. Stern, Robert E. Hawkins, Fiona C. Thistlethwaite · 2010 · Clinical Cancer Research
  2. Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
    Lawrence H. Fong, Serena S. Kwek, Shaun O’Brien, Brian Kavanagh, Douglas G. McNeel, VIVIAN K. WEINBERG, Amy Lin, Jonathan E. Rosenberg, Charles J. Ryan, Brian I. Rini et al. · 2009 · Cancer Research
  3. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
    Oh, David Y., Cham, Jason, Zhang, Li, Fong, Grant, Kwek, Serena S., Klinger, Mark, Faham, Malek, Fong, Lawrence · 2017 · Cancer Research
  4. Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
    Margaret K. Callahan, Jedd D. Wolchok, James Patrick Allison · 2010 · Seminars in Oncology
  5. The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
    Anna Maria Di Giacomo, MAURIZIO BIAGIOLI, Michele Maio · 2010 · Seminars in Oncology
  6. Genetically engineered T cells for cancer immunotherapy
    Dan Li, Xue Li, Wei-Lin Zhou, Yong Huang, Xiao Liang, Lin Jiang, Xiao Yang, Jie Sun, Zonghai Li, Weidong Han et al. · 2019 · Signal Transduction and Targeted Therapy
  7. Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
    Axel Hoos, Ramy A. Ibrahim, Alan J. Korman, Kald A. Abdallah, David Berman, Vafa Shahabi, Kevin M. Chin, Renzo M. Canetta, Rachel W. Humphrey · 2010 · Seminars in Oncology
  8. Improving T Cell Therapy for Cancer
    Ann Marie Leen, Cliona M. Rooney, Aaron Edward Foster · 2006 · Annual Review of Immunology
  9. Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
    Ahmad A. Tarhini · 2013 · Scientifica
  10. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
    Bergqvist, Viktoria, Hertervig, Erik, Gedeon, Peter, Kopljar, Marija, Griph, Håkan, Kinhult, Sara, Carneiro, Ana, Marsal, Jan · 2017 · Cancer Immunology Immunotherapy
  11. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells
    Nathalie Cools, Peter Ponsaerts, Viggo F. Van Tendeloo, Zwi Nisan Berneman · 2007 · Journal of Leukocyte Biology
  12. Rheumatic immune-related adverse events from cancer immunotherapy
    Leonard H. Calabrese, Cassandra M. Calabrese, Laura C. Cappelli · 2018 · Nature Reviews Rheumatology
  13. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
    R. M. S. Wong, Ronaldo Scotland, Roy Lau, Chenhui Wang, Alan J. Korman, W. Martin Kast, Jeffrey S. Weber · 2007 · International Immunology
  14. Next Generation of Immunotherapy for Melanoma
    John M. Kirkwood, Ahmad A. Tarhini, Monica C. Panelli, Stergios J. Moschos, Hassane M. Zarour, Lisa Helene Butterfield, Helen J Gogas · 2008 · Journal of Clinical Oncology
  15. Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
    Karl S. Peggs, Sergio A. Quezada, James Patrick Allison · 2008 · Immunological Reviews
  16. Novel technologies and emerging biomarkers for personalized cancer immunotherapy
    Jianda D. Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden Terry Maecker, David B. Page et al. · 2016 · Journal for ImmunoTherapy of Cancer
  17. Metastatic Melanoma – A Review of Current and Future Treatment Options
    Emanual Maverakis, Lynn A. Cornelius, G Bowen, T Phan, F Patel, Sarah Fitzmaurice, Y He, Barbara A. Burrall, C Duong, April M. Kloxin et al. · 2014 · Acta Dermato Venereologica
  18. Ipilimumab: controversies in its development, utility and autoimmune adverse events
    Jeffrey S. Weber · 2009 · Cancer Immunology Immunotherapy
  19. Mitigating the toxic effects of anticancer immunotherapy
    Tara C. Gangadhar, Robert H. Vonderheide · 2014 · Nature Reviews Clinical Oncology
  20. Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
    Mamta Joshi, Ben Whitelaw, M.T.P. Palomar, Yin Wu, Paul Carroll · 2016 · Clinical Endocrinology
  21. Anti-CTLA-4 therapy results in higher CD4 <sup>+</sup> ICOS <sup>hi</sup> T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
    Chen, Hong, Liakou, Chrysoula I., Kamat, Ashish, Pettaway, Curtis, Ward, John F., Tang, Derek Ng, Sun, Jingjing, Jungbluth, Achim A., Troncoso, Patricia, Logothetis, Christopher et al. · 2009 · Proceedings of the National Academy of Sciences
  22. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
    Sergio A. Quezada, Karl S. Peggs, Tyler R. Simpson, Yuelei Shen, Dan R. Littman, James Patrick Allison · 2008 · The Journal of Experimental Medicine
  23. Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy
    Pierpaolo Correale, Maria Saveria Rotundo, Maria Teresa Del Vecchio, Cinzia Remondo, Cristina Migali, Chiara Ginanneschi, Kwong Yok Tsang, Antonella Licchetta, Susanna Mannucci, Lucia Loiacono et al. · 2010 · Journal of Immunotherapy
  24. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo
    Oliver Martin Grauer, Stefan Nierkens, Erik J. Bennink, Liza W.J. Toonen, Louis Boon, Pieter Wesseling, Roger P.M. Sutmuller, Gosse J. Adema · 2007 · International Journal of Cancer
  25. Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
    Amod A. Sarnaik, Bin Yu, Daohai Yu, Dawn Morelli, MacLean S. Hall, Dilip Bogle, Lulu E. Yan, Stephan Targan, Jolie C. Solomon, Geoff M. Nichol et al. · 2010 · Clinical Cancer Research
  26. Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
    Marieke F. Fransen, Tetje Cornelia van der Sluis, FERRY A. OSSENDORP, Ramon Arens, Cornelis J.M. Melief · 2013 · Clinical Cancer Research
  27. Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
    Sara M. Mangsbo, Linda C. Sandin, Kerstin Anger, Alan J. Korman, Angelica Loskog, Thomas H. Tötterman · 2010 · Journal of Immunotherapy
  28. Regulatory T Cells and Human Disease
    Nathalie Cools, Peter Ponsaerts, Viggo F. Van Tendeloo, Zwi Nisan Berneman · 2007 · Clinical and Developmental Immunology
  29. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
    Erika von Euw, Thinle Chodon, Narsis Attar, Jason Jalil, Richard Chikara Koya, Begonya Comin-Anduix, Antoni Ribas · 2009 · Journal of Translational Medicine
  30. New drugs in melanoma: It’s a whole new world
    Alexander M.M. Eggermont, Caroline Robert · 2011 · European Journal of Cancer
  31. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
    Yago Pico de Coaña, Aniruddha Choudhury, Rolf W. Kiessling · 2015 · Trends in Molecular Medicine
  32. Ipilimumab in patients with cancer and the management of dermatologic adverse events
    Mario E. Lacouture, Jedd D. Wolchok, Gil Yosipovitch, Katharina Charlotte Kähler, Klaus Johannes BUSAM, Axel Hauschild · 2014 · Journal of the American Academy of Dermatology
  33. Immunotherapy of autoimmunity and cancer: the penalty for success
    Rachel R Caspi · 2008 · Nature reviews. Immunology
  34. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
    Martens, Alexander, Wistuba-Hamprecht, Kilian, Yuan, Jianda, Postow, Michael A., Wong, Phillip, Capone, Mariaelena, Madonna, Gabriele, Khammari, Amir, Schilling, Bastian, Sucker, Antje et al. · 2016 · Clinical Cancer Research
  35. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology
    Meagan Spencer Barbee, Adebayo Ogunniyi, Troy Z. Horvat, Thu-Oanh Dang · 2015 · Annals of Pharmacotherapy
  36. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
    Takeo Fujii, Rivka R. Colen, Mehmet Asım Bilen, Kenneth R. Hess, Joud Hajjar, Maria Eugenia Suarez-Almazor, Anas Alshawa, David S. Hong, Apostolia Maria Tsimberidou, Filip Jankú et al. · 2017 · Investigational New Drugs
  37. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
    Min, Le, Vaidya, Anand, Becker, Carolyn · 2011 · European Journal of Endocrinology
  38. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
    Roch Houot, Ronald Levy · 2008 · Blood
  39. Endocrine side effects of cancer immunotherapy
    Cukier, Priscilla, Santini, Fernando C, Scaranti, Mariana, Hoff, Ana O · 2017 · Endocrine-Related Cancer
  40. CTLA‐4: a key regulatory point in the control of autoimmune disease
    Kenneth J. Scalapino, David Daikh · 2008 · Immunological Reviews
  41. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
    Samantha R. Ellis, Aren T Vierra, Jillian Wong Millsop, Mario E. Lacouture, Maija H. Kiuru · 2020 · Journal of the American Academy of Dermatology
  42. Cancer immunotherapy
    Constantin N. Baxevanis, Sonia A. Perez, Michael Papamichail · 2009 · Critical Reviews in Clinical Laboratory Sciences
  43. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
    Anna Hryniewicz, Adriano Boasso, Yvette Edghill‐Smith, Monica Vaccari, Dietmar Fuchs, David J. Venzon, J. Nacsa, Michael R. Betts, W.-P. Tsai, Jean‐Michel Héraud et al. · 2006 · Blood
  44. Autoimmunity associated with immunotherapy of cancer
    Sally M. Amos, Connie P.M. Duong, Jennifer A. Westwood, David S. Ritchie, Richard Paul Junghans, Phillip Kevin Darcy, Michael H. Kershaw · 2011 · Blood
  45. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John Howard Sampson, Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, Darell D. Bigner · 2008 · Seminars in Immunology
  46. Current systemic therapy for metastatic melanoma
    Sanjiv S. Agarwala · 2009 · Expert Review of Anticancer Therapy
  47. Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
    Katharina C. Kaehler, Sarah Piel, Elisabeth Livingstone, Bastian Schilling, Axel Hauschild, Dirk Schadendorf · 2010 · Seminars in Oncology
  48. Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events
    Jennifer Kwak, Sree Harsha Tirumani, Annick D. Van den Abbeele, Phillip J. Koo, Heather A. Jacene · 2015 · Radiographics
  49. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
    Frank Stephen Hodi, Darryl A. Oble, Jan Drappatz, Elsa F. Velázquez, Nikhil H. Ramaiya, Naren Raj Ramakrishna, Arthur L. Day, Andrea Kruse, Suzanne Mac Rae, Axel Hoos et al. · 2008 · Nature Clinical Practice Oncology
  50. Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo
    Daniel J. Powell, Aloísio Felipe-Silva, Maria J. Merino, Mojgan Ahmadzadeh, Tamika Allen, Catherine L. Levy, Donald Edward White, Sharon A. Mavroukakis, Robert J. Kreitman, Steven A. Rosenberg et al. · 2007 · The Journal of Immunology
  51. Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
    Grazia Graziani, Lucio Tentori, Pierluigi Navarra · 2011 · Pharmacological Research
  52. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.
    Yvonne M. Saenger, Jedd D. Wolchok · 2008 · PubMed Central
  53. Biomarkers associated with checkpoint inhibitors
    Guillaume Manson, J. Norwood, Aurélien Marabelle, Holbrook E K Kohrt, Roch Houot · 2016 · Annals of Oncology
  54. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell–mediated suppression
    Xiao‐Tong Song, Kevin Evel-Kabler, Lei Shen, Lisa A. Rollins, Xue F. Huang, Si–Yi Chen · 2008 · Nature Medicine
  55. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
    Paolo A. Ascierto, Ester Simeone, Vanna Chiarion‐Sileni, Jacopo Pigozzo, Michele Maio, Maresa Altomonte, Michele Del Vecchio, Lorenza Di Guardo, Paolo Marchetti, Ruggero Ridolfi et al. · 2014 · Journal of Translational Medicine
  56. Functional Genetic Variations in Cytotoxic T-Lymphocyte Antigen 4 and Susceptibility to Multiple Types of Cancer
    Tong Sun, Yifeng Zhou, Ming Yang, Zhibin Hu, Wen Tan, Xiaohong Han, Yuankai Shi, Jiarui Yao, Yongli Guo, Dianke Yu et al. · 2008 · Cancer Research
  57. Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
    Antoni Ribas, Douglas C. Hanson, Dennis A. Noe, Robert Millham, Deborah J. Guyot, Steven H. Bernstein, Paul C. Canniff, Amarnath Sharma, Jesús Gómez-Navarro · 2007 · The Oncologist
  58. Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
    Ahmad A. Tarhini, Ernest Lo, David R. Minor · 2010 · Cancer Biotherapy and Radiopharmaceuticals
  59. Advances in immunotherapy for melanoma
    Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
  60. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
    Helen Conroy, Neil A. Marshall, Kingston H. G. Mills · 2008 · Oncogene
  61. Development of Peptide-Based Vaccines for Cancer
    Noraini Abd-Aziz, Chit Laa Poh · 2022 · Journal of Oncology
  62. Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
    Marieke F. Fransen, Marjolein Sluijter, Hans M. Morreau, Ramon Arens, Cornelis J.M. Melief · 2011 · Clinical Cancer Research
  63. A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
    Deirdre O’Mahony, John Charles Morris, Cate Quinn, Wendy Gao, Wyndham Hopkins Wilson, Barry L. Gause, Stefania Pittaluga, Sattva Swarup Neelapu, Margaret R. Brown, Thomas A. Fleisher et al. · 2007 · Clinical Cancer Research
  64. α-CTLA-4 mAb-associated Panenteritis
    Darryl A. Oble, Mari A. Mino-Kenudson, Jeffrey D. Goldsmith, Frank Stephen Hodi, Rania Medhat Seliem, Glenn Dranoff, Martín C. Mihm, Robert Paul Hasserjian, Gregory Yves Lauwers · 2008 · The American Journal of Surgical Pathology
  65. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
    Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, R. Pérez-Álvarez, Pilar Brito‐Zerón, Manuel Ramos‐Casals · 2017 · Expert Opinion on Drug Safety
  66. Cytotoxic T-Lymphocyte–Associated Antigen-4
    April K.S. Salama, Frank Stephen Hodi · 2011 · Clinical Cancer Research
  67. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
    Moreira, Alvaro, Leisgang, Waltraud, Schuler, Gerold, Heinzerling, Lucie · 2017 · Immunotherapy
  68. Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
    David Erwin Kleiner, David Berman · 2012 · Digestive Diseases and Sciences
  69. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data
    Wenjun Wang, Puyi Lie, Minzhang Guo, Jianxing He · 2017 · International Journal of Cancer
  70. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
    Kira Minkis, Benjamin C. Garden, Shenhong Wu, Melissa P. Pulitzer, Mario E. Lacouture · 2013 · Journal of the American Academy of Dermatology
  71. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
    de Coaña, Yago Pico, Wolodarski, Maria, Poschke, Isabel, Yoshimoto, Yuya, Yang, Yuan, Nyström, Maria, Edbäck, Ulrika, Brage, Suzanne Eghyazi, Lundqvist, Andreas, Masucci, Giuseppe V. et al. · 2017 · Oncotarget
  72. Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology
    Berna C. Özdemir, Chantal Csajka, Gian Paolo Dotto, Dorothea Wagner · 2018 · Journal of Clinical Oncology
  73. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
    Karl S. Peggs, Sergio A. Quezada, James Patrick Allison · 2009 · Clinical & Experimental Immunology
  74. Ocular Toxicity of Targeted Therapies
    Renouf, Daniel J., Velazquez-Martin, Juan P., Simpson, Rand, Siu, Lillian L., Bedard, Philippe L. · 2012 · Journal of Clinical Oncology
  75. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
    on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, Elena, Cartenì, Giacomo, Cortesi, Enrico, Giannarelli, Diana, De Giglio, Andrea, Sabbatini, Roberto, Buti, Sebastiano, Rossetti, Sabrina, Cognetti, Francesco et al. · 2019 · Journal for ImmunoTherapy of Cancer
  76. Endocrinological side-effects of immune checkpoint inhibitors
    Francesco Torino, Salvatore Maria Corsello, Roberto Salvatori · 2016 · Current Opinion in Oncology
  77. Ocular and orbital side-effects of checkpoint inhibitors: a review article
    Joelle S. Antoun, Chérif Titah, Isabelle Cochereau · 2016 · Current Opinion in Oncology
  78. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
    Riccardo Danielli, Ruggero Ridolfi, Vanna Chiarion‐Sileni, Paola Queirolo, Alessandro Testori, Ruth Plummer, Monica Boitano, Luana Calabrò, Costanza De Rossi, Anna Maria Di Giacomo et al. · 2011 · Cancer Immunology Immunotherapy
  79. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target
    Sandra D. Bohling, Kimberly H. Allison · 2008 · Modern Pathology
  80. Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
    Johnston, R. L., Lutzky, J., Chodhry, A., Barkin, J. S. · 2009 · Digestive Diseases and Sciences
  81. Clinical assessment of immune-related adverse events
    Aaron E. Sosa, Esther Lopez Cadena, Cristina Simon Olivé, Niki Karachaliou, Rafael Rosell · 2018 · Therapeutic Advances in Medical Oncology
  82. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients
    Xiaosong Li, Mark F. Naylor, Henry Le, Robert E. Nordquist, T. Kent Teague, C. Anthony Howard, Cynthia K. Murray, Wei R. Chen · 2010 · Cancer Biology & Therapy
  83. Engineering opportunities in cancer immunotherapy
    Laura Jeanbart, Melody A. Swartz · 2015 · Proceedings of the National Academy of Sciences
  84. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
    Jedd D. Wolchok, Jeffrey S. Weber, Omid Hamid, Célèste Lebbé, Michele Maio, Dirk Schadendorf, Veerle de Pril, Kevin N. Heller, Tai‐Tsang Chen, Ramy A. Ibrahim et al. · 2010 · PubMed Central
  85. Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
    Derek A. Wainwright, Mahua Dey, Alan Lee Chang, Maciej S. Lesniak · 2013 · Frontiers in Immunology
  86. Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature
    Evangelia Papavasileiou, Sashank Prasad, Suzanne K. Freitag, Lucia Sobrin, Ann‐Marie Lobo · 2015 · Ocular Immunology and Inflammation
  87. What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
    Caroline Robert, François Ghiringhelli · 2009 · The Oncologist
  88. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
    Antoine Millet, Anthony R. Martin, Cyril Ronco, Stéphane Rocchi, Rachid Benhida · 2016 · Medicinal Research Reviews
  89. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Fausto Petrelli, Giulia Grizzi, Michele Ghidini, Antonio Ghidini, Margherita Ratti, Stefano Panni, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Maria Chiara Parati et al. · 2019 · Journal of Immunotherapy
  90. Ipilimumab-induced acute severe colitis treated by infliximab
    Cécile Pagès, Jean Marc Gornet, Gentiane Monsel, Matthieu Allez, Philippe Bertheau, Martine Bagot, Célèste Lebbé, Manuelle A Viguier · 2013 · Melanoma Research
  91. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
    Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J. · 2017 · Oncotarget
  92. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
    For the German Dermatologic Cooperative Oncology Group (DeCOG), Katharina Charlotte Kähler, Thomas Eigentler, Anja Gesierich, Lucie Heinzerling, Carmen Loquai, Friedegund Elke Meier, Frank Meiß, Claudia Pföhler, Max S. Schlaak et al. · 2018 · Cancer Immunology Immunotherapy
  93. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
    Monica Girotra, Aaron Richard Hansen, Azeez Farooki, David J. Byun, Le Min, Ben Creelan, Margaret K. Callahan, Michael B. Atkins, Elad Sharon, Scott Joseph Antonia et al. · 2018 · JNCI Cancer Spectrum
  94. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
    Arun Rajan, Corey Allan Carter, Arlene W. Berman, Liang Cao, Ronan Joseph Kelly, Anish Thomas, Sean Khozin, Ariel Lopez Chavez, Isabella Bergagnini, Barbara Scepura et al. · 2014 · The Lancet Oncology
  95. Antibody and antibody fragments for cancer immunotherapy
    Weizhi Chen, Yuan Yang, Xiqun Jiang · 2020 · Journal of Controlled Release
  96. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
    Yong Fan, Wenhui Xie, Hong Huang, Yunxia Wang, Guangtao Li, Yan Geng, Yanjie Hao, Zhuoli Zhang · 2021 · Frontiers in Oncology
  97. Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
    Wenshi Wang, Daohai Yu, Amod A. Sarnaik, Bin Yu, MacLean S. Hall, Dawn Morelli, Yonghong Zhang, Xiuhua Zhao, Jeffrey S. Weber · 2012 · Journal of Translational Medicine
  98. Skin Reactions in a Subset of Patients With Stage IV Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent
    Samer H. Jaber, Edward W. Cowen, Leah R. Haworth, Susan L. Booher, David M. Berman, Steven A. Rosenberg, Samuel T. Hwang · 2006 · Archives of Dermatology
  99. Adoptive Transfer of Vaccine-Induced Peripheral Blood Mononuclear Cells to Patients with Metastatic Melanoma following Lymphodepletion
    Daniel J. Powell, Mark E. Dudley, Katherine Hogan, John R. Wunderlich, Steven A. Rosenberg · 2006 · The Journal of Immunology
  100. Dendritic cell vaccines in melanoma: From promise to proof?
    Willem Joost Lesterhuis, Erik H.J.G. Aarntzen, I. Jolanda M. de Vries, Danita H. Schuurhuis, Carl Gustav Figdor, Gosse J. Adema, Cornelis J.A. Punt · 2008 · Critical Reviews in Oncology/Hematology